Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Co-immunization of Cecolin (HPV) and Hecolin (HEV) Vaccines
NCT05415345Phase 4Unknown
- Sponsor
- Xiamen Innovax Biotech Co., Ltd.
- Start
- Oct 2021
- Primary completion
- Nov 2022
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of recombinant human papillomavirus bivalent (types 16, 18) vaccine, HEV 239 in human papillomavirus infection, hepatitis E (HEV), sponsored by Xiamen Innovax Biotech Co., Ltd.. Status: unknown.
02
Drugs
recombinant human papillomavirus bivalent (types 16, 18) vaccineHEV 239
03
Conditions
human papillomavirus infectionhepatitis E (HEV)
Beyond the preview
Go deeper on NCT05415345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05415345.